American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Aligos Therapeutics, Inc. (ALGS)

$4.78 -0.83% NASDAQ: ALGS · 15-min delayed

SOUTH SAN FRANCISCO, California
Public · NASDAQ: ALGS
82 employees

Visit website Follow

$25.2MMarket cap

$2.2MRevenue · FY2025

-$24.2MNet income

82Employees

ALGSNASDAQ

2020IPO

About Aligos Therapeutics, Inc.

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: ALGS
Employees: 82
IPO date: Oct 16, 2020
Headquarters: ONE CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO, California 94080
Phone: (800) 466-6059
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: ALGS Nasdaq
SEC CIK: 1799448
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Aligos Therapeutics, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/aligos-therapeutics-inc/"><img src="https://americancompanies.com/badge/aligos-therapeutics-inc.svg" alt="Aligos Therapeutics, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Aligos Therapeutics, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $2.2M
Net income: -$24.2M
Total assets: $88.5M
Market cap: $25.2M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: ALGS

$4.78 -0.83%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$4.08 $13.30

52-week range

Market cap: $25.2M
Shares outstanding: 5.3M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Oct 16, 2020

Aligos Therapeutics, Inc. (ALGS) Stock Price

Reported a net loss of $24.2M in FY2025.
Trading 64% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Aligos Therapeutics, Inc..

Write a review

Newsroom

News about Aligos Therapeutics, Inc.

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 GlobeNewswire Inc. · 2026-05-27 · positive Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection GlobeNewswire Inc. · 2026-04-16 · positive Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire Inc. · 2026-03-05 · positive Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) GlobeNewswire Inc. · 2026-02-23 · positive Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. · 2026-01-30 · neutral Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. · 2025-12-12 · neutral

News & sentiment via Polygon.io

FAQ

Aligos Therapeutics, Inc.: frequently asked questions

Is Aligos Therapeutics, Inc. an American company?

Aligos Therapeutics, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Aligos Therapeutics, Inc. headquartered?

Aligos Therapeutics, Inc. is headquartered in South San Francisco, California, United States.

Is Aligos Therapeutics, Inc. publicly traded?

Yes — Aligos Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol ALGS on the NASDAQ.

What does Aligos Therapeutics, Inc. do?

Aligos Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore